Utilization of genetically altered animals in the pharmaceutical industry

Toxicologic Pathology

Volumn 27, Issue 1, 1999, Pages 111-114

  Rudmann, Daniel G ^a   Durham, Stephen K ^b  

^a DUPONT COMPANY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Drug discovery; Knockout mice; Pharmaceuticals; Review; Risk assessment; Transgenics

Indexed keywords

CONFERENCE PAPER; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; IMMUNOTOXICITY; KNOCKOUT MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE;

ANIMALIA; MUS MUSCULUS; RODENTIA;

EID: 0032978418     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339902700121     Document Type: Conference Paper

References (51)

1. Askew GR, Doetschman T, and Lingrel JB (1993). Site-directed point mutations in embryonic stem cells: A gene-targeting tag-and-exchange strategy. Mol. Cell. Biol. 13: 4115-4124.
2. Atrip JH, Itescu S, Minanov OP, Kwiatkowski PA, and Michler PE (1997). Cardiac xenotransplantation. Curr. Opin. Cardiol. 12: 172-178.
3. Attar RM, Caamano J, Carrasco D, Iotsova V, Ishikawa H, Ryseck RP, Weih F, and Bravo R (1997). Genetic approaches to study Rel/ NF-kB/IkB function in mice. Cancer Biol. 8: 93-101.
4. Barinaga M (1994). Knockout mice: Round two [news; comment]. Science 265: 26-28. [Published erratum appears in Science 265: 855.]
5. Bedell MA, Jenkins NA, and Copeland NG (1996). Good genes in bad neighborhoods. Nat. Genet. 12: 229-232.
6. Beg AA, Sha WC, Bronson RT, Ghosh S, and Baltimore D (1995). Embryonic lethality and liver degeneration in mice lacking the ReIA component of NF-κB. Nature 376: 167-169.
7. Braselmann S, Graninger P, and Busslinger M (1993). A selective transcriptional induction system for mammalian cells based on Gal4-estrogen receptor fusion proteins. Proc. Natl. Acad. Sci. USA 90: 1657-1661.
8. Capecchi MR (1989). The new mouse genetics: Altering the genome by gene targeting. Trends Genet. 5: 70-76.
9. Charreau B, Tesson L, Soulillou JP, Pourcel C, and Anegon I (1996). Transgenesis in rats: Technical aspects and models. Transgenic Res. 5: 223-234.
10. Contrera JF and DeGeorge JJ (1998). In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals. Environ. Health Perspect. 106(suppl. 1): 71-80.
11. Copp AJ (1995). Death before birth: Clues from gene knockouts and mutations. Trends Genet. 11: 87-93.
12. Cuthbertson RA and Klintworth GK (1988). Transgenic mice - A gold mine for furthering knowledge in pathobiology. Lab. Invest. 58: 484-502.
13. de Vries A, van Oostrom CTM, Hofhuis FMA, Dortant PM, Berg RJW, de Gruijl FR, Wester PW, van Kreijl CF, Capel PJA, van Steeg H, and Verbeek SJ (1995). Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature 377: 169-173.
14. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montogomery CA, Butel JS, and Bradley A (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
15. Eastin WC (1998). The U.S. National Toxicology Program evaluation of transgenic mice as predictive models for identifying carcinogens. Environ. Health Perspect. 106(suppl. 1): 81-84.
16. Evans MJ and Kaufman MH (1981). Establishment in culture of pluripotential cells from mouse embryos. Nature 292: 154-156.
17. Feil R, Brocard J, Mascrez B, LeMeur M, Metzger D, and Chambon P (1996). Ligand-activated site-specific recombination in mice. Proc. Natl. Acad. Sci. USA 93: 10887-10890.
18. Fernandez-Salguero P, Pineau T, Hilbert DM, McPhail T, Lee SST, Kimura S, Nebert DW, Rudikoff S, Ward JM, and Gonzalez FJ (1995). Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 268: 722-726.
19. Frieberg T and Wolf CR (1996). Recombinant DNA technology as an investigative tool in drug metabolism research. Adv. Drug Deliv. Rev. 22: 187-213.
20. Garrick D, Fiering S, Martin DI, Whitelaw E (1998). Repeat-induced gene silencing in mammals (see comments). Nat. Genet. 18: 56-59.
21. Gordon JW and Ruddle FH (1981). Integration and stable germ line transmission of genes injected into mouse pronuclei. Science 214: 1244-1246.
22. Gu H, Marth JD, Orban PC, Mossmann H, and Rajewsky K (1994). Deletion of a DNA polymerase b gene segment in T cells using cell type-specific gene targeting. Science 265: 103-106.
23. Harvey M, McArthur MJ, Montgomery CAJ, Bradley A, and Donehower LA (1993). Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. 7: 938-943.
24. Houdebine LM (1994). Production of pharmaceutical proteins from transgenic animals. J. Biotechnol. 34: 269-287.
25. Jaenisch R (1976). Germ line integration and Mendelian transmission of the exogenous Moloney leukemia virus. Proc. Natl. Acad. Sci. USA 73: 1260-1264.
26. Jaenisch R (1988). Transgenic animals. Science. 240: 1468-1474.
27. Jaenisch R, Fan H, and Kroker B (1975). Infection of preimplantation mouse embyros and of newborn mice with leukemia virus: Tissue distribution of viral DNA and RNA and leukemogenesis in the adult animal. Proc. Natl. Acad. Sci. USA 72: 4008-4012.
28. Jaenisch R and Mintz B (1974). Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplantation blastocysts injected with viral DNA. Proc. Natl. Acad. Sci. USA 71: 1250-1254.
29. Kuhn R, Schwenk F, Aguet M, and Rajewsky K (1995). Inducible gene targeting in mice. Science 269: 1427-1429.
30. Lee SST, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, and Gonzalez FJ (1995). Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotrophic effects of peroxisome proliferators. Mol. Cell. Biol. 15: 3012-3022.
31. Lovik M (1997). Mutant and transgenic mice in immunotoxicology: An introduction. Toxicology 119: 65-76.
32. MacGregor JT, Farr S, Tucker JD, Heddle JA, Tice RR, and Turteltaub KW (1995). New molecular endpoints and methods in routine toxicity testing, Fundam. Appl. Toxicol. 26: 156-173.
33. Monro AM and MacDonald JS (1998). Evaluation of the carcinogenic potential of pharmaceuticals. Drug Safety 18: 309-319.
34. Morrison V and Ashby J (1994). A preliminary evaluation of the performance of the Muta Mouse (lacZ) and Big Blue (lacI) transgenic mouse mutation assays. Mutagenesis 9: 367-376.
35. Nebert DW and Duffy JJ (1997). How knockout mouse lines will he used to study the role of drug-metabolizing enzymes and their receptors during reproduction and development, and in environmental toxicity, cancer, and oxidative stress. Biochem. Pharmacol. 53: 249-254.
36. No D, Yao TP, and Evans RM (1996). Ecdysome-inducihle gene expression in mammalian cells and transgenic mice. Proc. Natl. Acad. Sci. USA 93: 3346-3351.
37. Perez P, Lira SA, and Bravo J (1995). Overexpression of RelA in transgenic mouse thymocytes: Specific increase on levels of the inhibitor IκBa. Mol. Cell. Biol. 15: 3523-3530.
38. Robinson D (1998). ILSI's role in the evaluation of alternative methodologies for the assessment of carcinogenic risk. Toxicol. Pathol. 26: 474-475.
39. Rosenberg MP (1997). Gene knockout and transgenic technologies in risk assessment: The next generation. Mol. Carcinog. 20: 262-274.
40. Ryffel B (1997). Impact of knockout mice in toxicology. Crit. Rev. Toxicol. 27: 135-154.
41. Sauer B and Henderson N (1990). Targeted insertion of exogenous DNA into the eukaryotic genome by the Cre recombinase. New Biol. 2: 441-449.
42. Shastry BS (1998). Gene disruption in mice: Models of development and disease. Mol. Cell. Biochem. 181: 163-179.
43. Shockett PE and Schatz DG (1996). Diverse strategies for tetracycline-regulated inducible gene expression. Proc. Natl. Acad. Sci. USA 90: 1657-1661.
44. Sibilia M and Wagner EF (1995). Strain-dependent epithelial defects in mice lacking the EGF receptor Science 269: 230-234.
45. Spencer DM (1996). Creating conditional mutations in mammals. Trends Genet. 12: 181-187.
46. St-Onge L, Furth PA, and Gruss P (1996). Temporal control of the Cre recombinase in transgenic mice by a tetracycline responsive promoter. Nucleic Acids Res. 19: 3875-3877.
47. Tennant RW, French JE, and Spalding JW (1995). Identifying chemical carcinogens and assessing potential risk in short-term bioassay using transgenic mouse models. Environ. Health Perspect. 103: 942-950.
48. Thomas KR and Capecchi MR (1987). Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 51: 503-512.
49. Travis J (1992). Scoring a technical knockout in mice. Science 256: 1392-1394.
50. Weih F, Durham SK, Barton DS, Sha WC, Baltimore D, and Bravo R (1997). p50-NF-κB complexes partially compensate for the absence of Rel B: Severely increased pathology in p50 ′ relB ′ double-knockout mice. J. Exp. Med. 185: 1-12.
51. Yamamota S, Urano K, Koizumi H, Wakana S, Hioki K, Mitsumori K, Kurokawa Y, Hayashi Y, and Nomura T (1998). Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenecity testing. Environ. Health Perspect. 106(suppl. 1): 57-69.